Violet Affleck reveals she and her mom, Jennifer Garner, had very different reactions to the Los Angeles wildfires
Violet Affleck has revealed something about her relationship with one of her famous parents as part of her college experience.
The 19-year-old daughter of actors Jennifer Garner and Ben Affleck is currently a freshman at Yale University.
The younger Affleck recently published an academic research paper in the school's Global Health Review, titled 'A Chronically Ill Earth: COVID Organizing as a Model Climate Response in Los Angeles.'
She began the paper by reflecting on an environmental disaster that she and Garner endured with many other Southern California residents, writing 'I spent the January fires in Los Angeles arguing with my mother in a hotel room.'
'She was shell-shocked, astonished at the scale of destruction in the neighborhood where she raised myself and my siblings,' Affleck wrote. 'I was surprised at her surprise: as a lifelong Angelena and climate-literate member of generation Z, my question had not been whether the Palisades would burn but when.'
The Los Angeles wildfires at the beginning of the year resulted in the loss of thousands of homes and buildings, especially in the Pacific Palisades and Altadena areas.
'As I chatted with adults in the hotel where we'd gone to escape the smoke, though, I found my position to be an uncommon one: people spoke of how long rebuilding would take, how much it would cost, and how tragically odd the whole situation had been,' Affleck wrote.
'The crisis was acute, a burst of bad luck. It had come from a combination of high winds and low rains – what, my little brother asked, did global warming have to do with the speed of the wind?' she continued. 'Outside, people wandered, faces covered by N95s. 'This feels like COVID,' said one wild-eyed woman clutching two leashed Yorkies. 'We're all in masks.''
Affleck addressed air quality and health issues before.
Last summer, the then 18-year-old spoke during the public comments portion of a Los Angeles County Board of Supervisors meeting and was seen making an impassioned plea in a video shared on X.
'I contracted a post-viral condition in 2019,' Affleck said at the meeting. 'I'm OK now, but I saw first-hand that medicine does not always have answers to the consequences of even minor viruses.'
She went on to request 'mask availability, air filtration and far-UVC lights in government facilities, including jails and detention centers, and mask mandates in county medical facilities.' Affleck advocated for free testing and treatment opportunities, while adding 'most importantly the county must oppose mask bans for any reason.'
'They do not keep us safer, they make vulnerable members of our community less safe and make everyone less able to participate in Los Angeles together,' she concluded in her speech.
Affleck is the eldest of three children of Garner and Ben Affleck, who married in 2005 and divorced in 2018. Their other children are Seraphina (who goes by Finn), 16 and Samuel, 13.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Seyltx Announces Positive Non-Human Primate (NHP) and Additional In Vivo Data for its Centrally Acting Inhibitor of GluN2B in Chronic Cough, Paving the Way for Optimized Later-Stage Phase 2 Trials
- Results will be presented at the American Cough Conference on June 7, 2025 - NHP receptor occupancy studies indicate increasing the dose in Phase 2 from 20 mg to 40-80 mg is likely to significantly increase cough suppression before receptor saturation - Oral administration in the Guinea pig model shows cough suppression up to 74% from baseline while staying under the NOAEL - Durability of cough suppression over time promises cough control with TID dose regimen and opens opportunity for once daily reformulation CAMBRIDGE, Mass., June 05, 2025--(BUSINESS WIRE)--Seyltx, Inc. a clinical-stage biotherapeutics company focused on developing innovative therapies to treat chronic cough and other neuronal hypersensitivity indications, today announced promising preclinical results for its lead compound, Ifenprodil. These new findings, to be presented at the American Cough Conference on June 7, 2025, offer critical insights into optimal dosing strategies and therapeutic durability, which will significantly inform the design of upcoming Phase 2 crossover studies planned for 2026. Ifenprodil, a NMDA antagonist with >200x selectivity towards the GluN2B subunit, is being developed to address refractory chronic cough (RCC), a significant unmet medical need, with a follow-on opportunity in chronic cough associated with Idiopathic Pulmonary Fibrosis (IPF-Cough). The company has already completed a Phase 2a trial in IPF-Cough at an exploratory low dose (20 mg TID) which yielded statistically significant reductions in objective cough count of 39% from baseline (at 12 weeks) and statistically significant improvement on multiple patient-reported outcomes. A NHP receptor occupancy (RO) study, conducted in collaboration with Yale University, was performed whereby rhesus monkeys underwent 120-minute PET scans following the intravenous injection of 135 ± 64 MBq (S)-[18F]OF-NB1 (tracer molecule). Ifenprodil was administered via 10-minute intravenous infusion at doses from 0.025 to 1 mg/kg (corresponding to oral human equivalent doses (HED) of 10-400 mg), with PET acquisition commencing 15' post-infusion. Dose-dependent GluN2B receptor occupancy was observed with a calculated EC50 (50% occupancy) of 0.04 mg/kg (HED of ~20 mg) and approximately 80% receptor occupancy predicted at 0.2 mg/kg (HED of ~80 mg). Doses between 40-80 mg TID are therefore expected to achieve 60-80% receptor occupancy, significantly enhancing therapeutic effects compared to the 20 mg TID dose used in the prior Phase 2a trial. In vivo studies conducted in Guinea pigs (GPs; 6-16 animals per group) assessed the antitussive effect of oral doses of Ifenprodil ranging from 1.5 mg/kg to 12 mg/kg (human equivalent doses of 20 to 160 mg). Ifenprodil demonstrated statistically significant (p<0.01) cough count reduction across the dose range of 39-74% following exposure to a tussive agent (1M citric acid). The lowest tested dose of 1.5 mg/kg (HED of 20 mg) resulted in a 39.1% reduction in cough count from baseline, consistent with the 39% reduction seen in the Phase 2a trial. Doubling this dose to an HED of 40 mg TID, which is well-tolerated in humans, improved the cough suppression to 56.0% reduction from baseline. A maximal reduction of 74.4% from baseline was observed at 12 mg/kg (HED 160 mg), a dose under the estimated NOAEL. The therapeutic effect proved durable, lasting up to 8 hours, even as systemic levels of Ifenprodil were cleared. This robust target engagement at the GluN2B subunit supports durable cough control with a TID (three times daily) dose regimen and opens the door for potential once-daily reformulation. These combined preclinical findings suggest an optimal human dose range of 40 to 80 mg for maximal therapeutic benefit, with the 80 mg dose yielding approximately 80% receptor occupancy, safely below levels that have shown adverse events in preclinical models. "These compelling preclinical results represent a significant leap forward in our understanding of Ifenprodil's potential to provide meaningful relief for patients suffering from chronic cough," said Dr. Dietrich Stephan, CEO of Seyltx. "The data not only confirms Ifenprodil's robust antitussive properties but also provides invaluable guidance on optimizing our dosing strategy for future clinical trials. We are excited to integrate these learnings into the design of our upcoming Phase 2 studies, bringing us closer to delivering a truly impactful therapy for this debilitating condition." Dr. Stephan further emphasized, "The promise of addressing GluN2B in the brain is that this target appears to be a central node in the cough reflex, likely providing significant cough control as a monotherapy without addictive potential across the population independent of etiology, if the preclinical data is translatable. The agent also has the potential to be used in combination with future peripherally acting therapies that might be approved." Seyltx plans to incorporate these key learnings into the design of its Phase 2 crossover studies, slated to commence in 2026. About Seyltx: Seyltx ( is a clinical stage biotherapeutics company focused on developing innovative therapies to treat chronic cough and other neuronal hypersensitivity indications. Its lead indication is refractory chronic cough, a significant unmet medical need, with a follow-on opportunity in chronic cough associated with Idiopathic Pulmonary Fibrosis (IPF-Cough). Seyltx's lead compound is Ifenprodil, an NMDA antagonist highly selective towards the GluN2B subunit, has completed a Phase 2a trial in chronic cough associated with IPF. Forward-Looking Statements: Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute "forward-looking statements" within the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects," "anticipates," "believes," "intends," "estimates," "potential," "possible," "projects," "plans," and similar expressions. Such statements, based as they are on the current expectations of management, inherently involve numerous important risks, uncertainties and assumptions, known and unknown, many of which are beyond Seyltx's control. View source version on Contacts Parag ShahChief Operating Officerpshah@ Connectez-vous pour accéder à votre portefeuille
Boston Globe
30-05-2025
- Boston Globe
CDC removes language that says healthy kids and pregnant women should get COVID shots
'The announcement from earlier this week sounded like CDC was going to fully withdraw any statement that could be construed as a recommendation for these vaccines in these populations,' said Jason Schwartz, a Yale University health policy researcher. 'It's not as bad as it could have been.' Advertisement Kennedy announced the coming changes in a On Thursday, the CDC updated its website. The agency said that shots may be given to children ages 6 months to 17 years who do not have moderate or severe problems with their immune systems. Instead of recommending the shots, the CDC now says parents may decide to get their children vaccinated in consultation with a doctor. A subtle update to a CDC page on the adult immunization schedule indicated a similar change for the recommendation for pregnant women, excluding them from the routine recommendation made for other adults. Advertisement 'The old COVID-19 vaccine recommendations for healthy children under 18 and for pregnant women have been removed from the CDC vaccine schedule,' a HHS spokesperson said in a statement. 'The CDC and HHS encourage individuals to talk with their healthcare provider about any personal medical decision.' That kind of recommendation, known as shared decision-making, still means health insurers must pay for the vaccinations, Childhood vaccination rates for COVID-19 are already low — just 13% of children and 23% of adults have received the 2024-25 COVID-19 vaccine, Talk of changing the recommendations has been brewing. As the COVID-19 pandemic has waned, experts have discussed the possibility of focusing vaccination efforts on people 65 and older — who are among those most as risk for death and hospitalization. A CDC advisory panel is set to meet in June to make recommendations about the fall shots. Among its options are suggesting shots for high-risk groups but still giving lower-risk people the choice to get vaccinated. A committee work group has endorsed the idea. But Kennedy, a leading anti-vaccine advocate before becoming health secretary, decided not to wait for the scientific panel's review. The new vaccine recommendation changes, their timing and the way there were announced have created confusion that can be 'incredibly harmful to the success of vaccination programs,' Schwartz said. 'It would be understandable if the public is completely baffled in terms of what the federal government thinks and what the science suggests ... about the evidence for the safety and value of these vaccines,' he added. Advertisement
Yahoo
29-05-2025
- Yahoo
New study uncovers troubling link between thyroid cancer and childhood exposure: 'These results are concerning'
Exposure to two common pollutants could increase the risk of pediatric thyroid cancer, according to a new study. The Yale University-led research found a "significant association" between exposure to ambient fine particulate matter (PM2.5) air pollution and outdoor artificial light at night and an increased risk of papillary thyroid cancer in children and young adults up to 19 years old. These exposures occurred during the perinatal stage of life, which is typically defined as the period that starts when pregnancy occurs and lasts up to a year after birth. The study, summarized in News Medical Life Sciences, found the strongest association between exposure and thyroid cancer in teenagers aged 15–19 and Hispanic children. "These results are concerning, especially given how widespread both of these exposures are," lead author Nicole Deziel said. "Fine particulate matter is found in urban air pollution due to automobile traffic and industrial activity, and artificial light at night is common, particularly in densely populated urban areas." She added that thyroid cancer is one of the fastest-growing cancers among children and adolescents. "Our study is the first large-scale investigation to suggest that these exposures early in life — specifically to PM2.5 and outdoor light at night — may play a role in this concerning trend." Children are often diagnosed with thyroid cancer at more advanced stages and with larger tumor sizes compared to adults, according to the university. Long-term effects for pediatric survivors can include temperature dysregulation, headaches, physical disabilities, and mental fatigue — these all can affect major life milestones such as education, employment, and having a family. Meanwhile, additional research has pointed to many other dangers of air and light pollution. One study found a connection between long-term exposure to air pollution and the development of psoriasis, a chronic and often debilitating skin condition. Another paper found a link between artificial light and cerebrovascular disease, a diagnosis that includes numerous conditions, including stroke, that cause blood flow problems in the brain. Light pollution can also impede survival for animals like coral and fireflies. A number of cities and countries are trying to cut down on air pollution to help protect public health and reduce planet-warming emissions. For instance, Wales is banning most new roadway projects, and a New York law will require all Lyfts and Ubers to be EVs by 2030. You can help by opting for more climate-friendly transportation, which can reduce traffic-related pollution for everyone. Plus, at least 18 states, Washington, D.C., and Puerto Rico have laws in place to reduce light pollution, according to Emerson Electric Co. Meanwhile, you can fight light pollution at home, too. DarkSky International recommends turning off unnecessary outdoor lights at night, avoiding the use of blue lights, and switching to LED lighting with warm-colored bulbs. Do you worry about air pollution in and around your home? Yes — always Yes — often Yes — sometimes No — never Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
